Smithkline Beecham Corporation

Glaxosmithkline LLC

Cytokinetics, Inc.

Other

Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Ligand Pharmaceuticals, Inc.

Kevin J Duffy

Juan I Luengo

Antony N Shaw

Julian Jenkins

Hong Jiang

Bradley Paul Morgan

David John Morgans, Jr

Xiangping Qian

Gustave Bergnes

Steven David Knight

Dashyant Dhanak

Luke W Ashcraft

Connie L Erickson-Miller

Bing Yao

Nicholas D Adams

Cynthia A Parrish

Jianchao Wang

Duke Fitch

Rosanna Tedesco

Han-Jie Zhou

Andrew I McDonald

Kenneth Wiggall

Jennifer Kuo Chen Huang

Sophie Visonneau

Duke M Fitch

Alan T Price

William Henry Miller

Jian Jin

Stephen F Miller

Ronggang Liu

Michael N Zimmerman

Andrea K Myers

Jerry Leroy Adams

Beth Adams Norton

Yiqian Lian

Lihua Zhang

Nannan Liu

Daniel F Eppley

Michael N Zimmermann

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Prolyl hydroxylase inhibitors

A compound of Formula (I) wherein Y, Y, X, X, R, R, R, R, R, R, R, and Rare as defined herein;and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Compounds

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Imidazole-benzamide anti-cancer agents

The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

N-substituted glycine derivatives: hydroxylase inhibitors

Imidazopyridinyl benzamide mitotic kinesin inhibitors

Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Imidazoyl-benzamide anti-cancer agents

Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Thrombopoietin mimetics

Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6 -dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.

5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one

Imidazopyridinyl-benzamide anti-cancer agents

Provided are compounds of Formula I and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Growing community of inventors

Collegeville, PA, United States of America

Kevin J Duffy